173 related articles for article (PubMed ID: 37927811)
21. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
[TBL] [Abstract][Full Text] [Related]
22. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
[TBL] [Abstract][Full Text] [Related]
23. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
[TBL] [Abstract][Full Text] [Related]
24. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model.
Park JH; Zhao M; Han Q; Sun Y; Higuchi T; Sugisawa N; Yamamoto J; Singh SR; Clary B; Bouvet M; Hoffman RM
Biochem Biophys Res Commun; 2019 Oct; 518(2):306-310. PubMed ID: 31421825
[TBL] [Abstract][Full Text] [Related]
26. Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
Park JH; Han Q; Zhao M; Tan Y; Higuchi T; Yoon SN; Sugisawa N; Yamamoto J; Bouvet M; Clary B; Singh SR; Hoffman RM
Tissue Cell; 2019 Dec; 61():109-114. PubMed ID: 31759402
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
[TBL] [Abstract][Full Text] [Related]
28. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.
Kawaguchi K; Igarashi K; Li S; Han Q; Tan Y; Miyake K; Kiyuna T; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
Oncotarget; 2018 Jan; 9(1):915-923. PubMed ID: 29416666
[TBL] [Abstract][Full Text] [Related]
29. High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.
Hoffman RM; Murakami T; Kawaguchi K; Igarashi K; Tan Y; Li S; Han Q
Methods Mol Biol; 2019; 1866():149-161. PubMed ID: 30725414
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
Cells; 2019 May; 8(5):. PubMed ID: 31052611
[TBL] [Abstract][Full Text] [Related]
31. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
[TBL] [Abstract][Full Text] [Related]
33. Survival efficacy of the combination of the methioninase gene and methioninase in a lung cancer orthotopic model.
Miki K; Xu M; An Z; Wang X; Yang M; Al-Refaie W; Sun X; Baranov E; Tan Y; Chishima T; Shimada H; Moossa AR; Hoffman RM
Cancer Gene Ther; 2000 Feb; 7(2):332-8. PubMed ID: 10770644
[TBL] [Abstract][Full Text] [Related]
34. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model.
Miyake K; Kiyuna T; Li S; Han Q; Tan Y; Zhao M; Oshiro H; Kawaguchi K; Higuchi T; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Murakami T; Singh AS; Li Y; Nelson SD; Eilber FC; Bouvet M; Hiroshima Y; Chishima T; Matsuyama R; Singh SR; Endo I; Hoffman RM
Chemotherapy; 2018; 63(5):278-283. PubMed ID: 30673664
[TBL] [Abstract][Full Text] [Related]
35. Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
Kubota Y; Han Q; Masaki N; Hozumi C; Hamada K; Aoki Y; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Dec; 42(12):5819-5823. PubMed ID: 36456116
[TBL] [Abstract][Full Text] [Related]
36. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy.
Tan Y; Xu M; Tan X; Tan X; Wang X; Saikawa Y; Nagahama T; Sun X; Lenz M; Hoffman RM
Protein Expr Purif; 1997 Mar; 9(2):233-45. PubMed ID: 9056489
[TBL] [Abstract][Full Text] [Related]
37. Oral Recombinant Methioninase Inhibits Diabetes Onset in Mice on a High-fat Diet.
Tashiro Y; Han Q; Tan Y; Sugisawa N; Yamamoto J; Nishino H; Inubushi S; Sun YU; Zhu G; Lim H; Aoki T; Murakami M; Bouvet M; Hoffman RM
In Vivo; 2020; 34(3):973-978. PubMed ID: 32354882
[TBL] [Abstract][Full Text] [Related]
38. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
[TBL] [Abstract][Full Text] [Related]
39. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
[TBL] [Abstract][Full Text] [Related]
40. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
